What is the recommended dosage of ondansetron (generic name for Zofran) for a child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ondansetron Dosing for Pediatric Patients

The recommended dose of ondansetron for children is 0.15 mg/kg per dose (maximum 16 mg per dose) administered intravenously, intramuscularly, or orally, with this weight-based dosing providing safe and effective antiemetic control across all pediatric age groups. 1, 2

Standard Weight-Based Dosing

  • The universal pediatric dose is 0.15 mg/kg per administration, with an absolute maximum single dose of 16 mg regardless of the calculated weight-based dose. 1, 2, 3

  • For practical application in common pediatric weights:

    • 25 kg child: 3.75 mg per dose 2
    • 30 kg child: 4.5 mg per dose 2
    • 35 kg child: 5.25 mg per dose 2
    • 40 kg child: 6 mg per dose 2
  • The same 0.15 mg/kg dosing applies across all routes of administration (IV, IM, or oral). 1, 2

Route-Specific Administration Guidelines

  • Intravenous administration should be given over 2-5 minutes at 0.15 mg/kg. 3

  • Intramuscular dosing uses the identical 0.15 mg/kg dose when IV access is difficult or unavailable. 2, 3

  • Oral formulations (tablets, oral disintegrating tablets, oral soluble film) follow the same weight-based calculation of 0.15 mg/kg. 1

Age-Specific Considerations

  • Ondansetron should only be used in children ≥6 months of age, as safety data in younger infants is insufficient. 2

  • The standard 0.15 mg/kg dosing applies uniformly to children aged 6 months through adolescence (2-18 years). 1, 2

  • Pediatric patients demonstrate increased clearance compared to adults, but the 0.15 mg/kg dose accounts for this pharmacokinetic difference. 4

Clinical Context-Specific Dosing

Chemotherapy-Induced Nausea and Vomiting

  • For highly emetogenic chemotherapy: Administer 0.15 mg/kg IV or IM (maximum 16 mg) 30 minutes before chemotherapy, then repeat at 4 and 8 hours after the first dose. 2

  • Combining ondansetron with dexamethasone significantly improves antiemetic efficacy in chemotherapy settings—this combination is superior to ondansetron monotherapy. 1, 2, 5

  • For moderate-emetic-risk chemotherapy, ondansetron combined with dexamethasone is the recommended regimen. 1

  • For low-emetic-risk chemotherapy, ondansetron monotherapy at standard dosing is appropriate. 1

Acute Gastroenteritis

  • A single oral dose of 0.15 mg/kg (maximum 16 mg) reduces recurrent vomiting, need for IV fluids, and hospital admissions in children with acute gastroenteritis. 6

  • The dose range of 0.13-0.26 mg/kg shows similar efficacy, with no advantage to higher doses within this range. 7

  • Ondansetron is recommended for children >4 years with acute gastroenteritis and vomiting. 1

Postoperative Nausea and Vomiting

  • A single dose of 0.15 mg/kg (maximum 16 mg) administered 1 hour before induction of anesthesia is effective. 2

  • Ondansetron 0.1-0.15 mg/kg IV is superior to droperidol or metoclopramide for preventing postoperative emesis in pediatric surgical procedures. 5

Radiation-Induced Nausea and Vomiting

  • For radiation therapy, ondansetron 8 mg oral or 0.15 mg/kg IV is administered once daily before radiation therapy. 8

  • The adult dosing table from oncology guidelines shows 8 mg oral or 0.15 mg/kg IV for various radiation therapy risk categories, which can guide pediatric dosing at the weight-based equivalent. 8

Critical Safety Considerations

  • Ondansetron can prolong the QT interval in a dose-dependent manner—exercise special caution in children with cardiac disease or congenital long QT syndrome. 2, 3

  • The 16 mg maximum dose provides an appropriate safety margin to minimize QT prolongation risk. 2

  • Ondansetron is generally well tolerated, with the most common adverse events being mild headache, constipation, and diarrhea. 5

  • Ondansetron should not replace appropriate fluid and electrolyte therapy, particularly in gastroenteritis management. 1

Dosing Frequency by Indication

  • Single-dose regimen: For acute gastroenteritis or postoperative nausea, one dose of 0.15 mg/kg is typically sufficient. 6, 7

  • Multiple-dose regimen: For chemotherapy-induced nausea, administer 0.15 mg/kg at 0,4, and 8 hours on the day of chemotherapy. 2

  • For persistent vomiting requiring repeated dosing, the 0.15 mg/kg dose can be repeated, but the total daily dose should not exceed 48 mg (three 16 mg doses). 1

Enhanced Efficacy Strategy

  • Consider adding dexamethasone 4-12 mg IV (weight-adjusted for smaller children) for improved antiemetic control, particularly in high-risk situations such as highly emetogenic chemotherapy. 2, 3

  • The combination of ondansetron with dexamethasone is significantly more efficacious than ondansetron alone across multiple clinical contexts. 1, 5

Common Pitfalls to Avoid

  • Do not underdose based on conservative calculations—use the full 0.15 mg/kg up to the 16 mg maximum. 1, 2

  • Avoid using ondansetron in infants <6 months of age due to insufficient safety data. 2

  • Do not use ondansetron as a substitute for proper hydration therapy in gastroenteritis—it is an adjunct to oral rehydration. 1

  • Screen for cardiac conditions before administration, as QT prolongation is the primary safety concern. 2, 3

References

Guideline

Ondansetron Dosing in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ondansetron Dosing Guidelines for Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ondansetron and Dicyclomine Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ondansetron: a novel antiemetic agent.

Southern medical journal, 1993

Research

Antiemetic Drug Use in Children: What the Clinician Needs to Know.

Journal of pediatric gastroenterology and nutrition, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.